Lymphoma. Hodgkinlymfomen and non-Hodgkin's disease
Information on current developments in both regular and alternative or complementary treatments and resources for lymphoma - non-Hodgkin's lymphoma and Hodgkin's disease at all stages.
Recent articles in left column more or less in alphabetical order classified
Experiences of cancer patients with complementary approaches can be found by experience stories on our website and there are also some videos of experiences of cancer patients with complementary approaches to see. To click on video button top left of this page. Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.
Cancer Immunotherapies to BiovaxID (TM), lymfklier: a Vaccination-immunotherapies in non-Hodgkin gives good results from phase I and II and phase III trials.
This article is a few hours worked. Lookup, translate, places etc. If you want to support us you can do so through a donation anonymous or not. Any amount is welcome no matter how small. Click here if you want to help us to keep cancer-news online We are an ANBI organization and so your donation is tax-deductible.
11 January 2012:
Interesting to mention is in addition to the information below a summary article of the approach with radio therapy-irradiation in combination with shapes of chemo and immuuntherapeutische resources including Zevalin and Bexxar and Yttrium-90: Radioimmunotherapy or Non-Disease Lymphoma: From the ' Magic Bullets ' to ' Radioactive Magic Bullets '
In the abstract state this, but click on this link for the full study report.
Down state information about immunotherapies with BiovaxID ®. If you click here you can read and see how you as a patient may obtain BiovaxID ® can:
Source: Radioimmunotherapy (RIT) or lymphoma with Zevalin and Bexxar was approved by FDA in 2002 and 2003, respectively, for the treatment of relapsed or refractory follicular CD20 + B-cell non-Hodgkin's lymphoma ´ s. In 2009, Zevalin was also approved for consolidation therapy in patients with follicular non-Disease lymphoma that achieve a partial or complete response to first-line chemotherapy. For follicular lymphoma patients, the overall response and progression-free survival rates have significantly improved since the implementation or ride. The predominant hematological toxicity complication or ride is that is usually manageable. There are ongoing trials to further define the expanding role of RIDE as first line or concomitant therapy in the treatment of lymphoma as well as for certain antibiotic resistant infections and aggressive malignancies. There is also growing interest in the development of newer protocols for increased and more uniform dose delivery resulting in better outcomes and improved patient survival. This review will primarily focus on the role or RIDE in treatment of non-Disease lymphoma, which is established or clinical utility and FDA approved. The mechanism of RIDE, available radionuclides and pharmacokinetics, therapy administration, clinical utility and toxicities, and future directions would be discussed.
26 http://www.accentia.net May 2006: source:
Thanks to Maurice who made pointing. We have tried to find but all abstracts of studies on this are listed in Pubmed abstract immunotherapies with entry "abstract not available". Likely to influence the presentation in June a.s. not. Below, however, some more information about the results so far with BiovaxID (TM) that companies if they are true really good results. But do take into consideration that this information is presented by the producer who has an interest in there so all with a good presentation. It is therefore regrettable that the real results from the earlier trials are not available in an objective database. But perhaps after 2 June after the presentation at ASCO 2006. Below some information in English about this immuuntherapeutische approach and the results so far from the earlier trials and why a phase III study is approved that runs now.
Association Between Molecular Remission and Disease-Free Survival in Non-Hodgkins Lymphoma at About Nine Years follow-up To Be Presented
TAMPA, Fla.--(BUSINESS WIRE)--May 24, 2006--
Accentia Biopharmaceuticals majority-owned subsidiary, Biovest International, Inc., to present BiovaxID Phase 2 long-term follow-up data at the annual meeting of American Society of Clinical Oncology
Accentia BioPharmaceuticals, Inc. (NASDAQ: ABPI) and its majority-owned subsidiary, Biovest International, Inc. (OTCBB: BVTI), will present long-term follow-up data from the company's Phase 2 trial of BiovaxID (TM) at the annual meeting of the American Society of Clinical Oncologists (ASCO). The meeting is the annual educational and scientific professional organization representing physicians who treat event or this cancer patients. This year's meeting will be held June 2 through June 6, 2006, at the Georgia World Congress Center in Atlanta.
Accentia's abstract, entitled "Idiotype Vaccine Therapy or Follicular Lymphoma in First Remission: Association of t (14: 18) and Disease Free Survival in a Phase II Cohort," will be presented as part of the Scientific Program in the Lymphoma and Plasma Cell Disorders General Poster Session.
What have the results been with the vaccine?
The first clinical trials were conducted at Stanford in 1988 and involved 41 patients with leads to paralysis (slow growing) form of B-cell lymphoma. These patients were given chemotherapy which they had either a complete response (no detectable tumor) or a partial response (reduction in tumor burden or at least 50%). Of the 41 patients, 32 were in remission following their first course of therapy. The remaining 9 patients achieved remission following two or three courses of chemotherapy. The vaccine was given to patients in remission and positive immune response was seen in20 of the 41 patients given the vaccine. This includes 14 of the 32 patients who were in complete remission following the first course of chemotherapy. The patients were followed and the long term follow up was published in ' Blood ' in May 1997. The long term follow-up results showed that the patients who had a positive immune response had a median time to relapse or 7.9 years (time between remission and reappearance or detectable cancer) compared to 1.3 years in those who did not have a positive immune response. In 1997 when the study was published, the median long term survival of all 41 patients was analyzed. The Stanford physician investigators concluded that the long term survival was significantly longer than those in the vaccination patients patients with identical diseases that had not received the vaccination.
The second trial (phase II) was conducted by the National Cancer Institute (NCI) and published in "Nature Medicine" in October 1999. In this trial, 20 patients were enrolled who had achieved complete remission after chemotherapy (however using a very sensitive DNA-based test, 11 of the 20 considered in complete remission were shown to still have cancer cells in their blood). Of these 20 patients, 95% had significant positive immune response to the vaccine. This included 73% (8 of the 11) who had been determined to still have cancer cells in the blood after chemotherapy. At the end of the study (23 to 53 months), 90% of patients remained in complete remission. Follow up after seven years, median time to relapse had exceeded 7 years in the group who had received the vaccine. BiovaxID Cancer Vaccine (TM), Personalized Anti-from Biovest International, Produces Long Term Clinical Remission and 95 Percent Overall Survival in Patients with Follicular Non-Disease Lymphoma in Phase 2 Clinical Trial TAMPA, Fla.--(BUSINESS WIRE)--Jan. 10, 2006--Tumor-Free Survival from Investigational Vaccine Compares Favorably with Published Reports or Chemotherapy Alone, and Regi man That Include Rituxan (R) (1) While There is No Consensus as to What Constitutes a "Cure" or Non-Disease Lymphoma, Phase 2 Results Are Encouraging Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI), and its subsidiary, Biovest International, Inc. (OTCBB: BVTI), jointly reported long-term follow-up data from its Phase 2 clinical trial of BiovaxID (TM), a personalized vaccine for follicular lymphoma, during a poster session at the 47th Annual Meeting of the American Society of Hematology in Atlanta, December 11, 2005. (Abstract # 2441) In this single-arm, Phase 2 study, patients with follicular B-cell Non-Disease Lymphoma (NHL) in continuous first clinical remission six months following PACE chemotherapy were treated with a series of vaccinations or subcutaneous BiovaxID. BiovaxID is comprised or tumor-derived protein Id (tumor antigen) conjugated to KLH as a carrier protein administered with GM-CSF (granulocyte macrophage colony stimulating factor). With a medianfollow-up of 9.2 years, 45 percent of patients remained in continuous first clinical remission at their most recent follow-up (either in 2004-2005), and the overall survival rate was 95 percent. Furthermore, median disease free survival for the patient cohort was 96.5 months (8.0 years). Based on historical data these results suggest a clinically significant advance on current expectations or disease progression. "The results of this Phase 2 study compare very favorably with chemotherapy alone and with CHOP-R where the median disease-free survival-is 2.2 years and 6.9 years respectively. The ongoing Phase 3 trial of BiovaxID vs. non-specific immune stimulation should help to clarify the role of vaccine therapy in patients with follicular lymphoma, "said Barry Gause, M.D., co-investigator for the clinical trial at the National Cancer Institute (NCI). "We are encouraged by these long term follow-up data from our Phase 2 study," said Angelos Salesjö, M.D., Director of Product Development, Accentia Biopharmaceuticals. "These results underscore the potential of BiovaxID (TM) as a promising personalized therapeutic vaccine for follicular lymphoma. Patients, physicians, payors and are understandably requesting that, at some point in the battle against cancer, expensive cancer therapeutics need to start to provide cures. Because this disease is considered incurable with existing therapies we are particularly pleased with the reported rate of overall survival without tumor recurrence, which is the gold standard for cancer therapeutics. " BiovaxID is designed to evoke the power of each patient's immune system, priming it to recognize and eliminate detecting pre-cancerous lymphoma cells, while sparing normal B-cells. BiovaxID uses complete high fidelity copies of each patient's unique tumor antigen produced in a hybridoma cell line exclusively licensed from Stanford University. Other vaccines currently being evaluated for the treatment of follicular lymphoma are made by molecular cloning and splicing, and incorporate only a portion of the patient's tumor antigen. Background on immunotherapeutics for non-Disease lymphoma Rituxan is a passive immunotherapeutic consisting of a monoclonal antibody administered intravenously. The monoclonal antibody is directed to an antigen (CD20) present on all B-lymphocytes. Accordingly, Rituxan promotes the elimination of detecting pre-cancerous and normal B-lymphocytes bearing this antigen. Rituxan therapy is typically repeated as necessary at intervals in order to control the lymphoma. Annual sales for Rituxan are about $ 1.5 B. BiovaxID is an active immunotherapeutic which stimulates the production of antibodies anti-tumor cell-mediated immune response to schizophrenia and a detecting pre-cancerous B-lymphocytes but not to normal B-lymphocytes. As an active immunotherapeutic BiovaxID, may also provide ongoing immunosurveillance for recurrent tumors.
